New diabetes drug MK-1403 enters human testing
NCT ID NCT07242469
First seen Nov 21, 2025
Summary
This early-stage study tests an experimental drug called MK-1403 in people with type 2 diabetes. The main goals are to check if the drug is safe and tolerable, and to see how it behaves in the body. Researchers will also measure its effect on a marker of inflammation (hsCRP). About 52 participants will receive either MK-1403 or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Pharma CR, LLC ( Site 0003)
RECRUITINGMiami, Florida, 33147, United States
Contact Phone: •••-•••-••••
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)
ACTIVE_NOT_RECRUITINGSpringfield, Missouri, 65802, United States
-
ProSciento Inc. ( Site 0001)
RECRUITINGChula Vista, California, 91911, United States
Contact Phone: •••-•••-••••
-
QPS-MRA, LLC ( Site 0004)
RECRUITINGSouth Miami, Florida, 33143, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-1403 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for type 2 diabetes that also reduces inflammation.
What could go wrong
This is an early Phase 1 trial with only 52 participants, so it is primarily testing safety and dosing. The drug may not prove effective or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.